SCHEMBL3474587

SCHEMBL3474587

O=C(Nc1cccc(Cl)c1)c1ccc(-c2cc(C(F)(F)F)nn2-c2ccccc2Cl)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 3/20 0.55
NR1H2 P55055 3/20 0.55
NR1H3 Q13133 3/20 0.55
MAPT P10636 6/20 0.53
SMN1; SMN2 Q16637 4/20 0.53
TP53 P04637 1/20 0.53
POLB P06746 1/20 0.50
ORAI1 Q96D31 1/20 0.48
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
NCOR2 Q9Y618 2/20 0.48
PPARG P37231 1/20 0.48
NR2E3 Q9Y5X4 1/20 0.48
NR3C2 P08235 1/20 0.47
HDAC3 O15379 1/20 0.46
HDAC4 P56524 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC7 Q8WUI4 1/20 0.46
HDAC2 Q92769 1/20 0.46
HDAC10 Q969S8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3471324 0.92 MAPT (0.59) RXRANR1H2NR1H3MAPTSMN1; SMN2
SCHEMBL3472847 0.91 RXRA (0.54) RXRANR1H2NR1H3MAPTSMN1; SMN2
SCHEMBL3473163 0.91 MAPT (0.62) RXRANR1H2NR1H3MAPTSMN1; SMN2
SCHEMBL3472362 0.91 RXRA (0.54) RXRANR1H2NR1H3MAPTSMN1; SMN2
SCHEMBL3474844 0.91 RXRA (0.55) RXRANR1H2NR1H3MAPTSMN1; SMN2
SCHEMBL3472273 0.91 MAPT (0.56) RXRANR1H2NR1H3MAPTSMN1; SMN2
SCHEMBL14624228 0.91 RXRA (0.53) RXRANR1H2NR1H3MAPTSMN1; SMN2
SCHEMBL3473316 0.91 RXRA (0.53) RXRANR1H2NR1H3MAPTSMN1; SMN2
SCHEMBL3471973 0.91 RXRA (0.55) RXRANR1H2NR1H3MAPTSMN1; SMN2
SCHEMBL3471938 0.90 ORAI1 (0.60) RXRANR1H2NR1H3MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
CN-101248048-B Imidazole based LXR modulators EXELIXIS INC 2013-08-28 CN disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
CN-101248048-A Imidazole based LXR modulators EXELIXIS INC (US) 2008-08-20 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331295-A1 MODULATORS OF LXR NR1H2, NR1H3, NR1H4 RXRA 18/4885NR1H2 1/4885NR1H3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.